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Abstract
The human hematopoietic disorder named Tn syndrome has been ascribed to an acquired stem cell mutation resulting in
loss of b-1,3-galactosyltransferase activity in affected Tnq cells of the hematopoietic lineages. Recently, we could
demonstrate that this deficiency is due to a repression of a functional allele of the b-1,3-Gal-T gene since treatment of Tnq
 .T-lymphocytes from a patient R.R. afflicted with the Tn-syndrome with 5-azacytidine or Na n-butyrate resulted in
 . wre-expression of the Thomsen–Friedenreich TF antigen, the product of b-1,3-Gal-T activity M. Thurnher, S. Rusconi,
E.G. Berger, Persistent repression of functional allele can be responsible for galactosyltransferase deficiency in Tn
 . xsyndrome, J. Clin. Invest. 91 1993 2103–2110 . To reduce these observations to a common pathogenetic mechanism
responsible for the Tn-syndrome, more Tn patients need to be investigated. Here, we describe similar Tnq T-lymphocytes
cultured ex vivo from patient M.Z. whose Tnq syndrome was newly recognized. Tnq and TFq T-lymphocyte cultures
were characterized by flow cytometry and measurement of b-1,3-Gal-T and shown to be deficient in Tnq cells.
Furthermore, Tnq cells were treated with 5-azacytidine and Na n-butyrate as described before. Reoccurrence of
b-1,3-Gal-T activity dependent epitopes on the cell surface of Tnq cells was shown by flow cytometry. These support the
notion of b-1,3-Gal-T gene repression as a common pathogenetic mechanism underlying the Tn-syndrome. q 1998 Elsevier
Science B.V.
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1. Introduction
The Tn syndrome, formerly called permanent
mixed-field polyagglutinability, is a rare disease char-
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acterized by the exposure of the Tn antigen 2 on the
w xcell surface of a variable portion of blood cells 1,2 .
The main characteristics have recently been reviewed
w x3 . Briefly, unmasking of a-GalNAc residues ensues
2 The carbohydrate antigen structures are as follows: Tn-anti-
gen: GalNAca1-ThrrSer peptide. Thomsen–Friedenreich anti-
 .gen TF-antigen : Galb 1-3GalNAca1-ThrrSer-peptide. Sialo-
syl-Tn: Neu5Aca 2-6GalNAca1-ThrrSer peptide.
0925-4439r98r$19.00 q 1998 Elsevier Science B.V. All rights reserved.
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 .from a deficiency of b-1,3- O galactosyltransferase
w x4,5 which normally substitutes GalNAc with b-Gal
in a 1,3 linkage thereby forming the Thomsen–Frie-
denreich antigen. The deficiency is the result of an
acquired stable repression of Gal-T transcription
which is still poorly understood. Repression occurs
only in a certain proportion of all blood cells and is
partially reversed by treatment with 5-azacytidine or
w xNa butyrate 6 . Reactivation of the enzyme was
followed by re-expression of the Thomsen–Frie-
denreich antigen which could be detected after cleav-
age of NeuAc by sialidase. In addition, CD43
 .leukosialin which did not react with a NeuAc-de-
pendent mAb in Tnq cells became detectable after
treatment with 5-azacytidine.
The observation of re-expression of b-1,3-Gal-T
after transcriptional activators such as 5-azacytidine
 .  .5-azaC or Na n-butyrate NaB were made in a
 .single male patient R.R. whose deficient T-
lymphocytes carrying the Tnq phenotype were
cloned ex vivo. In theory, the mechanism of stable
repression might have been an exception to the rule
since no other cases have been investigated and no
molecular probes nor antibodies to the enzyme are
available at the present time. Thus, investigations on
any other case will be important to answer the ques-
tion whether the observations made in case R.R. are
representative for the Tn syndrome or whether they
pertained to an exceptional case.
We report here the data obtained in another case
 .M.Z. and show that T lymphocytes derived from
this patient reacted in a qualitatively similar way to
treatment with 5-azaC and Na n-butyrate as the cells
derived from patient R.R.
2. Materials and methods
2.1. Patient
Freshly collected heparinized peripheral blood was
obtained from patient M.Z. female, 70 yr at the time
.of venipuncture with established Tn-syndrome.
Hematological data are reported in Section 3.
2.2. Reagents
 .Bovine serum albumin BSA was purchased from
 .Fluka, phytohemagglutinin PHA from Wellcome.
 .Vibrio cholerae neuraminidase VCN was from
 .Bohringer Mannheim. UDP-galactose UDP-Gal was¨
w14 x  .from Fluka, and UDP- C -Gal 329 mCirmmol
was from Amersham. Benzyl 2-acetamido 2-deoxy
a-D-galactopyranoside N-acetylgalactosamine-
.  .OCH Ph , 5-azacytidine 5-azaC , and Na n-butyrate2
 .NaB were purchased from Sigma.
2.3. Antibodies
 .IE3 anti-Tn, IgG2a mAb has been previously
w xdescribed 7 and was kindly provided by H. Clausen,
Copenhagen. DF-T1 sialic acid dependent anti-
. CD43, IgG1 mAb and HB-T1 anti-Thomsen–Frie-
.denreich antigen, IgM mAb were purchased from
Dakopatts. As a secondary antibody a FITC-con-
 .  .jugated goat F ab anti-mouse Ig Dakopatts was2
used.
2.4. Culture media
 .Iscove’s modified Dulbecco’s medium IMDM
.was supplemented with 1% volrvol of a 100=
mixture of non-essential amino acids, 50 mgrml
gentamycin, 60 mgrml anti-PPLO agent, final con-
centrations respectively, 1 mM sodium pyruvate, and
 .  .10% volrvol heat-inactivated 568C, 60 min fetal
 .  .calf serum FCS IMDMrFCS . FCS was obtained
from Seromed, the other products were purchased
from Gibco. For the cultivation of T-lymphocytes,
IMDM–FCS was supplemented with 1000 Urml
recombinant human IL-2 Proleukin was purchased
.  .from EuroCetus IMDMrFCSrIL-2 .
2.5. Isolation of peripheral blood lymphocytes
Blood was drawn by venipuncture and kept for 24
h at 48C for shipping from Paris to Zurich. Peripheral
 .blood mononuclear cells PBMC were isolated by
gradient centrifugation using Ficoll–Paque Phar-
.macia .
2.6. Separation of Tnq T-lymphocytes by magnetic
( )cell sorting MACS
For positive selection of Tnq T-lymphocytes,
mononuclear cells were isolated from patient M.Z.’s
blood. Initially, T-lymphocytes were activated with 1
 .mgrml phytohemagglutinin PHA in IMDMrFCS
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and 1000 Urml IL-2 and kept in culture for 3 days.
The T-lymphocytes were collected, pelleted and re-
 . 6suspended in 200 ml IE3 anti-Tn per 10 Tnq
cells. Cells were incubated for 30 min at 48C, then
 .washed with 1% BSA wrv rPBS and centrifuged.
The cell pellet was resuspended in 80 ml 1% BSA
 . 7wrv rPBS per 10 cells. To this cell suspension, 20
ml rat anti-mouse IgG2aqb magnetic microbeads
 . 7Miltenyi Biotec per 10 cells were added and kept
in the refrigerator at 6–128C for 15 min. Afterwards,
the cells were washed with 50 ml 1% BSA
 .wrv rPBS and centrifuged. The cell pellet was
 .resuspended in 1 ml 1% BSA wrv rPBS and ap-
plied to the top of separation column type A2 in
MACS separator with a flow rate defined by a 24G
needle. The non-magnetic fraction, which consisted
of Tn-cells was collected by elution of the loaded
 .column with 5 ml 1% BSA wrv rPBS. For wash-
ing the column the needle was changed to 22G, the
column was removed from the separator and the cells
were flushed to the top of the column using the side
 .syringe with 5 ml 1% BSA wrv rPBS. The column
was placed back in the separator and the cells were
allowed to pass through in order to remove all weakly
bound cells. This wash fraction was not collected.
For the magnetic fraction which consists of Tnq
 .cells, a syringe with 24 ml 1% BSA wrv rPBS was
connected to the top of the column, the needle was
removed, and the column was taken out from the
separator. The magnetic fraction was eluted by a fast
flushing of the cells with the eluent attached on top
of the column. Both the non-magnetic and magnetic
fractions were centrifuged and the resulting cell pellet
was further used.
2.7. T-lymphocyte lines and culture
T-lymphocytes were expanded and maintained in
culture by periodic restimulation in intervals of 2–3
weeks. For restimulation, 6=105 T-lymphocytes and
6  .10 feeder cells at 5400 rad irradiated PBMC were
incubated in 2 ml of IMDMrFCSrIL-2 and 1 mgrml
PHA. T-lymphocytes were cloned by limiting dilu-
 .tion in Terasaki plates Nunc at 1.0 cells per well
 .20 ml in the presence of 1 mgrml PHA and
0.5=106 feeder cells. After 10 days, microtiter wells
were scored microscopically and growing cells were
transferred to a 96-well plate, restimulated and fur-
ther propagated.
2.8. Sialidase treatment
For desialylation, 106 cells in 100 ml PBS, pH 7.4
.containing 0.5% wrv BSA were treated with 2 mU
VCS for 30 min at 378C. Cells were washed twice
 .with 1% FCS wrv PBS.
2.9. Flow cytometry
T-cells were stained at densities of 106 cells per
100 ml at 48C for 30 min. Cells were first stained
with the appropriate primary mAb, followed by
FITC-conjugated goat anti mouse Ig. After each incu-
bation the cells were washed twice with 1% FCS
 .wrv PBS. Controls were treated the same way
except that the primary antibody was excluded. After
 .the final wash, cells were fixed in PBSr2% vrv
formaldehyder0.1% BSA and stored at 48C in the
dark until analysis.
Cells were analyzed for immunofluorescence on a
EPICS Profile flow cytometer, collecting data for 104
cells for each histogram. Possible interference by
feeder cells was excluded by gating the lymphocyte
population.
2.10. Drug treatment of T-lymphocytes
T-lymphocyte cultures were restimulated as de-
 .scribed above in 24 well plates 2 mlrwell . During
peak growth phase, usually on day 5 after restimula-
tion, half of the supernatant was removed. 5-azaC
was freshly prepared as a 4 mM stock solution in
IMDM and diluted into IMDMrFCSrIL-2 to yield a
2-fold solution of which 1 ml was added to the
T-lymphocytes. After treatment, cells were allowed
to grow for 1 week. Untreated Tnq and TFq
T-lymphocytes from the same restimulation batch
were used as control cells. NaB was prepared as a 0.5
M stock solution in sterile water, this stock was
diluted in one step into IMDMrFCSrIL-2 and added
to the T-lymphocytes during log growth phase. The
T-lymphocytes were exposed to NaB for 24, 48, and
72 h after which they were analyzed by flow cytome-
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try. Again, untreated Tnq T-lymphocytes were used
as controls.
2.11. Assay for UDPGal: GalNAc-R b1-3 galactosyl-
( ) ( )transferase b1-3 Gal-T EC 2.4.1.122
Preparation of cell lysates. Cells were washed
twice and solubilized by the addition of 200 ml
 .ice-cold 2% Triton X-100r125 mM MES pH 7.0
per 107 cells. The cell lysate was kept on ice for 30
min. Afterwards, the cell lysate was centrifuged in an
Eppendorf centrifuge at full speed at 48C and the
supernatant was collected for protein determination.
Protein concentration was determined using the micro
 .BCA protein assay Pierce and BSA as a standard
according to the manufacturer’s instruction. The pro-
tein concentrations of the cell lysates were adjusted
to 1 mgrml.
b 1-3 Gal-T activity was measured using N-acetyl-
galactosamine-OCH Ph as exogenous acceptor sub-2
strate. Controls including reaction mixtures stopped
 .immediately zero time . In a total of 100 ml, 75 mM
 .  .MES pH 7.0 , 25 mM MnCl , 1% vrv Triton2
X-100, 2 mM N-acetylgalactosamine-OCH Ph, 0.252
w14 x  4 .mM UDP- C -Gal 10 cpmrnmol were incubated
with 50 mg T-lymphocyte protein for 4 h at 378C.
The reaction was stopped by adding 400 ml ice-cold
20 mM natrium tetraborater1 mM EDTA and passed
 .over a 1 ml packed-bed volume AG 1-X8 column
y  .Cl form Bio-rad . The column was washed with 3
ml of water. To the flow through, 10 ml of scintilla-
 .tion fluid Insta-Gel from Packard was added and
radioactivity was measured in a b-scintillation
counter.
3. Results
3.1. Clinical background of patient M.Z.
 .M.Z. female, born 1923 was found to be affected
by the Tnq syndrome on routine blood typing as
part of a medical check-up because of ‘cold feet’.
Clinical work-up did not reveal any relevant patho-
logical finding except the blood group anomaly. The
hematological data obtained at the time of venipunc-
ture are given on Table 1. They were all within the
normal range.
Table 1
Hematological laboratory values of patient M.Z.
12  .Red blood cells 4.5=10 rl 4.2–5.4
9  .White cell count 3.5=10 rl 4–10
9  .Platelets count 156=10 rl 200–400
 .Hematocrit 39.8% 42"2
 .Hb 13.7 grdl 14"2
Differential count
 .Neutrophils 39% 45–70
 .Lymphocytes 54% 20–40
 .Monocytes 6% 3–7
 .Eosinophils y 1–3
 .Basophils y 0–0.5
 .Mean corpuscular 87.9 87"5
3 .volume mm
 .Mean corpuscular 34.4% 34"2
hemoglobin concentration
 .MCHC
Hematological data on patient M.Z. obtained at time of venipunc-
ture.
w xNormal values according to Ref. 8 are shown in brackets.
3.2. Tnq phenotype in T-lymphocytes from patient
M.Z.
To determine the percentage of circulating Tnq
T-lymphocytes of patient MZ, PBMC’s were isolated
from blood collected previously in Paris and shipped
to Zurich. These PBMCs were stimulated for T-
lymphocyte activation and propagation by phyto-
hemagglutinin and interleukin-2. After the prolifera-
tion phase, the cells were collected and a flow cyto-
metric analysis for the detection of Tn- and TF-anti-
gen expression was performed. Only 3.2% of the
 .T-lymphocytes were Tnq Fig. 1a , but when siali-
dase-treated cells were stained for the TF antigen no
 .negative cells could be detected not shown .
3.3. Enrichment and characterization of Tn q
T-lymphocytes
Since we were able to detect a small subpopulation
of Tnq T-lymphocytes in peripheral blood from
patient M.Z., we first enriched the Tnq subset by
MACS. For this purpose, the cells were cultivated by
periodic restimulation and then subjected to immuno-
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magnetic separation by positive selection using the
IE3 mAb to Tn. After two rounds of separation we
obtained two fractions, one with 93% TFq T-
 .lymphocytes not shown and another with 98% Tnq
T-lymphocytes as determined by flow cytometric
 .analysis with mAb IE3 Fig. 1b .
These subsets were further enriched by limiting
dilution, which was carried out as described in Sec-
tion 2. The cell cultures obtained from limiting dilu-
tion were periodically restimulated and expanded.
For characterization of the Tnq and TFq cul-
tures, representative cultures expressing the Tn- or
TF-phenotype were chosen. Flow cytometric analysis
showed that the Tnq culture expressed the Tn anti-
gen, while showing marginal staining with anti-TF
 .mAb Fig. 2c which may be ascribed to interfering
feeder cells. The TFq culture expressed the TF
antigen, but only after sialidase treatment, indicating
 .complete sialylation of the TF antigen Fig. 2a .
b 1-3 Gal-T enzyme activity was determined in lysates
of both this Tnq and TFq cells. No evidence for
 .enzyme activity was found in Tnq cells Fig. 2d ,
whereas the TFq culture contained b 1-3 Gal-T
 .activity Fig. 2c .
 .Fig. 1. Flow cytometric analysis of T-lymphocytes from patient M.Z. PHA-activated T-lymphocytes from patient M.Z. a and the
 .Tnq -enriched cell fraction after immunoseparation b were stained for Tn expression with mAb IE3 followed by secondary antibody
 .  .solid line . Negative controls consisting of secondary antibody only were included dotted line .
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 .  .  .Fig. 2. Flow cytometric and enzymic characterization of T-lymphocyte cultures Normal TFq T-lymphocytes culture no. 9 a and Tnq T-lymphocytes culture no. 7
 .  .  .c were stained for Tn expression using mAb IE3 solid line or for TF expression using mAb HB-T1 after sialidase treatment bold line . Negative controls consisting of
 .  .  .secondary antibody only were included dotted line . b 1-3 Gal-T activity was determined in TFq cells b and in Tnq cells d as described in Section 2.
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Fig. 3. Re-expression of TF and CD43 antigens in Tnq cells after 5-azaC treatment. Tnq T-lymphocytes were cultivated in media containing 2 mM 5-azaC or inNeuAc
control media for 1 week as written in Section 2. The expression of Tn, TF, and CD43 antigens using the respective mAbs was analyzed. Controls includedNeuAc
pretreatment with sialidase. The arrows indicate altered phenotypes due to 5-azaC treatment.
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3.4. Induction of O-linked glycan antigens in Tnq
T-lymphocytes by 5-azaC and NaB
To test whether 5-azaC and NaB, two transcrip-
tional activators, can also induce re-expression of the
sialylated TF antigen in patient M.Z., we exposed
Tnq and TFq T cell cultures from M.Z. to 5-azaC
and NaB.
For the 5-azaC induction, Tnq cells were treated
once with 2 mM 5 days after restimulation during
peak proliferation. After 1 week of growth, the cells
were analyzed for re-expression of TF and sialic acid
dependent CD43 epitopes. During cell cultivation, the
exposure to 5-azaC led to a sizable reduction in the
number of surviving cells when compared to un-
treated cells.
Flow cytometric analysis of untreated and treated
Tnq cells is presented in Fig. 3. The Tn antigen was
expressed on Tnq cells with and without prior siali-
dase treatment indicating that the Tn epitope was not
 .sialylated Fig. 3c,d . After treatment with 5-azaC,
the percentage of cells not expressing the Tn pheno-
 .type increased by 15% Fig. 3a, arrow . Pretreatment
with sialidase did not increase the Tn signal indicat-
ing absence of sialosyl-Tn epitopes on treated cells
 .Fig. 3b . The TF antigen was not detectable on Tnq
 .cells Fig. 3g,h . 5-azaC induced some expression of
the TF antigen on Tnq cells as revealed after siali-
 .dase treatment Fig. 3f , while no TF antigen could
be detected on treated Tnq cells without prior siali-
 .dase treatment Fig. 3e . This suggests that a sialy-
lated TF epitope was expressed de novo on Tnq
cells after 5-azaC exposure. The following measure-
ments with DF-T1, a mAb recognizing CD43
 .leukosialin in a sialic acid-dependent manner, con-
firmed these observations. Untreated Tnq cells
bound DF-T1 only marginally, and none after siali-
 .dase treatment Fig. 3k,l . Again, after 5-azaC treat-
ment, the DF-T1 epitope was expressed on a subset
 .of Tnq cells Fig. 3i, arrow . This binding could be
 .abrogated after sialidase treatment Fig. 3j . A second
pulse of 5-azaC after 7 days did not further increase
 .the re-expression of the TF epitope not shown .
 .Na n-butyrate NaB , a transcriptional activator,
was also applied in re-expression experiments at a
concentration of 2 mM. Cells were treated with NaB
during log growth phase, usually on day 3 after
restimulation for 24, 48, and 72 h. The treated and
untreated cells, resp., were then immediately ana-
lyzed for re-occurrence of the CD43 epitope andNeuAc
decrease of the Tn epitope. As can be seen from Fig.
4, the induction of CD43 and decrease of TnNeuAc
expression is demonstrated in a time-dependent man-
ner. After 24 h, little increase in CD43 expres-NeuAc
sion in the treated cells as compared to untreated
cells could be shown, while a decrease in Tn expres-
 .sion was already evident Fig. 4a . After 48 h, an
induction of CD43 was observed, which contin-NeuAc
 .ued after 72 h Fig. 4b,c . The subset not expressing
the Tn-phenotype after 48 and 72 h was larger than
the one exhibiting increased CD43 expression atNeuAc
 .the respective times Fig. 4b,c indicating de novo
expression of epitopes not recognized by DF-T1 nor
by IE3 monoclonal antibodies.
4. Discussion
For many years, the Tn-syndrome had been con-
sidered to be due to an acquired somatic mutation of
the enzyme b-1,3-galactosyltransferase for review
w x.see Ref. 3 . Recently, we were able to show that a
reversal of the Tnq phenotype was possible by
exposure of Tnq T-lymphocytes to 5-azacytidine, an
agent interfering with methylation or to Na-butyrate,
an inhibitor of histone deacetylation. Thus, a stable
repression of an intact b-1,3-galactosyltransferase
gene is responsible for the Tn-syndrome in the exam-
w xined patient R.R. 6 . It is possible that in early
hemopoietic progenitor cells, the b-1,3-galacto-
syltransferase locus becomes inhibited, thus giving
rise to repressed clones in various lineages.
As the Tn-syndrome is a very rare hematological
disease, the prevalence being below 1 in 150,000, we
were able till now to perform investigations only in
 .one Tn-patient R.R.
Fig. 4. Flow cytometry of Tnq cells after NaB treatment. Tnq T-lymphocytes were cultivated in media containing 2 mM NaB or in
 .  .  .normal media, as described in Section 2, and collected after the a 24, b 48, and c 72 h and prepared for flow cytometric analysis. The
 .  .expression of Tn mAbrE3 and CD43 antigens mAb DF-T1 in treated and in untreated cells was analyzed. The arrows indicateNeuAc
altered phenotypes due to NaB treatment.
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Various factors other than expression of functional
glycosyltransferase contribute to proper glycan
w xbiosynthesis and their cell-specific expression 9 . A
stable glycosylation defect similar to the Tn-syn-
drome in many respects is paroxysmal nocturnal
 .hemoglobinuria PNH . PNH is also an acquired
disorder of clonal origin, where a stable population of
blood cells is unable to synthesize the glycosylphos-
 . w xphatidylinositol GPI anchor 10 . New data dis-
closed that despite the many apparent similarities of
PNH with the Tn syndrome, PNH is a heterogeneous
disorder resulting from loss of function mutations. It
was, therefore, unclear, whether the stable repression
of b-1,3-galactosyltransferase as found in patient R.R.
was more the exception than the rule since in this
case no loss of function mutation seems to be in-
volved. Therefore, in order to infer if the pathogene-
sis of the Tn-syndrome in patient R.R. is unique, it is
necessary to investigate additional patients. Thus, this
report represents one additional step towards an an-
swer to the question whether a common pathogenetic
mechanism underlies the Tn syndrome.
Intriguingly, patient M.Z. did not present any
hematological symptoms due to the Tn-syndrome
such as mild hemolysis or moderate thrombopenia.
From the clinical data obtained at the time of diagno-
sis, no hematological abnormality was detected Ta-
.ble 1 . A small subpopulation of 3.2% Tnq cells
could be detected in peripheral blood lymphocytes
from M.Z. Since homogeneous cell lines are required
for reactivation studies, Tnq and TFq cells were
enriched in order to be further used for limiting
dilution. The resulting cell cultures were character-
ized by flow cytometry and enzymic activity mea-
surements.
Reactivation of b-1,3-galactosyltransferase, as
monitored by the re-occurrence of the TF antigen by
flow cytometry, was induced by treatment of Tnq
 .cells from patient M.Z. with 5-azacytidine Fig. 3 .
Additionally, a sialylated epitope on CD43, the major
O-glycan bearing protein on T-lymphocytes, was ex-
pressed de novo on Tnq cells after treatment with
 .5-azaC and NaB Figs. 3 and 4 . We observed that
after 5-azaC, the percentage of cells not exhibiting
the Tn phenotype remained constant independent of
 .sialidase treatment Fig. 3a,b . This suggests that
5-azaC does not induce sialylation of the Tn antigen.
When treated cells were compared to untreated cells,
10% of the cells showed binding to anti-TF and
anti-CD43 antibodies, while 15% cells showed aNeuAc
 .decreased binding to anti-Tn antibodies Fig. 3 . This
suggests the expression of an epitope different from
TF or CD43 .NeuAc
The results obtained after NaB treatment of Tnq
cells were qualitatively similar to those obtained after
 .5-azaC Fig. 4 . The induction of CD43 andNeuAc
decrease of Tn expression was demonstrated in a
time dependent manner. The subpopulation not ex-
pressing the Tn antigen after 48 and 72 h was larger
than the subpopulation exhibiting increased
CD43 expression at the respective times Fig.NeuAc
.4 . This also suggests the expression of an epitope
not detectable by the antibodies used. NaB has been
shown to exert a variety of changes in glycosylation
of mammalian cells, e.g., NaB induced a 90% reduc-
 .tion of a-2,6- N sialyltransferase enzyme activity
w xand mRNA level in HepG2 cells 11 . Core 2 b-1,6-
 .N-acetylglucosaminyltransferase C2GnT is usually
expressed in low amounts in CHO cells, but after
NaB treatment the enzyme activity is significantly
w xincreased 12 . C2GnT is also upregulated during
T-lymphocyte activation, leading to branching of the
w xTF antigen 13 . As a result of NaB treatment, it is
possible that C2GnT is also upregulated. This would
lead to additional b 1-6 branched TF structures 3 not
detectable by the antibodies used.
Gene regulation of glycosyltransferases is a topic
of ongoing research. 5-azaC, as perturbant of DNA
methylation is being used to investigate activation of
otherwise silent genes. In CHO cells, 5-azaC induced
an activation of a-1,2-fucosyltransferase not ex-
w xpressed in untreated cells 14 .
Recently, it was demonstrated that DNA methyla-
 .tion plays a key role in CD43 leukosialin gene
expression. The leukosialin promoter is not meth-
 .ylated in cells synthesizing leukosialin leukocytes ,
while it is methylated in those cells lacking leukosialin
w x15 . Leukosialin production was induced by 5-azaC
in non-producing cells. Thus, it is not excluded that
detectability of leukosialin after treatment with 5-azaC
also results from direct induction of the leukosialin-
polypeptide in addition to enhanced galactosylation
3 The structure formed by C2GnT is the following so-called
. w xCore 2 : Galb 1-3 GlcNAcb 1-6 GalNAca1-ThrrSer-peptide.
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of its Tn-epitopes. Further work is needed to delin-
eate a possible parallelism between leukosialin and
b-1,3-galactosyltransferase expression.
Further investigations of the molecular basis of the
transcriptional repression of b-1,3-Gal-T in the Tn-
syndrome are of great interest. These results could
lead to the explanation of other glycosylation defi-
ciencies where incomplete O-galactosylation is at-
tributed a pathogenetic role as in the case of IgA1
w xnephropathy 16 .
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